Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) shares jumped 69.6% to $15.01 after dropping 24% on Tuesday.
Guggenheim Initiates Coverage On SCYNEXIS with Buy Rating, Announces Price Target of $8
Guggenheim analyst Vamil Divan initiates coverage on SCYNEXIS (NASDAQ:SCYX) with a Buy rating and announces Price Target of $8.
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 325 companies set new 52-week lows.
SCYNEXIS Announces $3M National Institutes Of Health Grant Has Been Awarded To Case Western Reserve University Researchers To Study Second Generation Fungerp To Fight Drug-Resistant Fungi
Researchers to study the potential of SCY-247 to fight Candida auris (C.auris), a multidrug-resistant pathogen named as an "urgent threat" by the Centers for Disease Control (CDC) and included in the
Provention Bio’s Second Try, Apellis’s Eye Disorder Drug Review, 3 Adcom Verdicts And More: November’s Key PDUFA Catalysts Biotech Investors Must Know
Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.
Biopharma Veteran Ivor Macleod Joins SCYNEXIS As Chief Financial Officer
SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Ivor Macleod, an accomplished biopharma
Looking Into SCYNEXIS’s Return On Capital Employed
Benzinga Pro data, SCYNEXIS (NASDAQ:SCYX) reported Q2 sales of $1.32 million. Earnings fell to a loss of $13.35 million, resulting in a 144.82% decrease from last quarter.